High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.

INTRODUCTION Patients with life-threatening advanced non-small cell lung cancer (NSCLC) who harbor an exon 20 deletion and/or insertion mutation (EGFRex20 + ) have limited effective treatment options. The high dose 3rd generation tyrosine kinase inhibitor (TKI) osimertinib shows promising in vitro activity in EGFRex20 + NSCLC tumors. METHODS The POSITION20 is a single arm phase II, multicenter study investigating 160 mg osimertinib in patients with EGFRex20+, T790M negative NSCLC. We allowed patients to be treatment naïve and to have asymptomatic brain metastases. The primary endpoint was overall response rate (ORR). Secondary outcomes were duration of response (DoR), progression free survival (PFS), overall survival (OS), and treatment related adverse events (trAEs). RESULTS From June 2018 to October 2021, 25 patients were enrolled across five centers in the Netherlands. The median age was 70 years (range, 47-87), 20 patients (80%) were women, and the median number of previous lines of therapy was 1 (range, 0-3). The exon 20 mutations were clustered between A763 and L777. The most common exon 20 mutations were p.(N771_H773dup) (n = 3) and p.(A767_V769dup) (n = 3). The ORR was 28% (95% CI, 12-49%), including seven partial responses, with a median DoR of 5.3 months (range, 2.7-27.6). The median PFS was 6.8 months (95% CI, 4.6-9.1) and the median OS was 15.2 months (95% CI, 14.3-16.0). The most common trAEs were diarrhea (72%), dry skin (44%), and fatigue (44%). The primary reason for discontinuation was progressive disease in 14 patients (56%). CONCLUSION The POSITION20 study showed modest antitumor activity in patients with EGFRex20 + NSCLC treated with 160 mg osimertinib, with a confirmed ORR of 28% and acceptable toxicity.

[1]  S. Kobayashi,et al.  EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios , 2021, Cells.

[2]  S. Matsumoto,et al.  A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. , 2021, Lung cancer.

[3]  Jing Wang,et al.  Structure-based classification predicts drug response in EGFR-mutant NSCLC , 2021, Nature.

[4]  N. Girard,et al.  Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Jänne,et al.  Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations. , 2021 .

[6]  Gregory Riely,et al.  Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study. , 2021 .

[7]  M. Socinski,et al.  Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). , 2021, Journal of Clinical Oncology.

[8]  J. Neal,et al.  Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial. , 2021, Cancer discovery.

[9]  Y. Zhang,et al.  Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations. , 2020, Lung cancer.

[10]  S. Kobayashi,et al.  Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. , 2020, The oncologist.

[11]  M. Socinski,et al.  Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. , 2020 .

[12]  L. Sequist,et al.  ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. , 2020 .

[13]  E. Felip,et al.  New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. , 2020, Critical reviews in oncology/hematology.

[14]  S. Kobayashi,et al.  EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors , 2020, JTO clinical and research reports.

[15]  E. Schuuring,et al.  Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. , 2019, Lung cancer.

[16]  Ying Cheng,et al.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.

[17]  D. Heo,et al.  Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19) , 2019, Annals of Oncology.

[18]  S. Kobayashi,et al.  TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations , 2019, Molecular Cancer Research.

[19]  Minghui Wang,et al.  EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer , 2019, BMC Cancer.

[20]  J. McPherson,et al.  Diverse EGFR Exon 20 Insertions and Co‐Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  F. Cappuzzo,et al.  A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. , 2018, Journal of thoracic disease.

[22]  Kwok-Kin Wong,et al.  Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer , 2018, Nature Medicine.

[23]  R. Rosell,et al.  Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer. , 2018, Translational lung cancer research.

[24]  P. Jänne,et al.  CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Chia-Chi Lin,et al.  Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[27]  T. Mitsudomi,et al.  Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. , 2016, The Lancet. Oncology.

[28]  P. Jänne,et al.  Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies , 2016, Cancer Chemotherapy and Pharmacology.

[29]  T. Betsuyaku,et al.  In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer , 2015, Oncotarget.

[30]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[31]  Geoffrey R. Oxnard,et al.  Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer , 2013, Science Translational Medicine.

[32]  Suzanne E Dahlberg,et al.  Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  Marc Ladanyi,et al.  EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics , 2013, Molecular Cancer Therapeutics.

[34]  Joseph O. Deasy,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .

[35]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[36]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[37]  N. Normanno,et al.  The role of EGF-related peptides in tumor growth. , 2001, Frontiers in bioscience : a journal and virtual library.

[38]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[39]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.